205 related articles for article (PubMed ID: 1873625)
21. 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression.
Nandam LS; Jhaveri D; Bartlett P
Clin Exp Pharmacol Physiol; 2007; 34(5-6):546-51. PubMed ID: 17439430
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.
Hrdina PD
J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):10-8. PubMed ID: 1931931
[No Abstract] [Full Text] [Related]
23. Introduction: treating depression and anxiety to remission.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 15():3-4. PubMed ID: 14658983
[No Abstract] [Full Text] [Related]
24. Drug treatment of anxiety and depression.
Fox T
Practitioner; 1991 Sep; 235(1506):681-3. PubMed ID: 1796034
[No Abstract] [Full Text] [Related]
25. Introduction: advances in the pharmacotherapy of depression.
Lapierre YD
J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):3. PubMed ID: 1931934
[No Abstract] [Full Text] [Related]
26. Therapeutic potential of serotonin antagonists in depressive disorders.
Wood MD; Thomas DR; Watson JM
Expert Opin Investig Drugs; 2002 Apr; 11(4):457-67. PubMed ID: 11922855
[TBL] [Abstract][Full Text] [Related]
27. Panic disorder: the potential role of serotonin reuptake inhibitors.
Sheehan DV; Zak JP; Miller JA; Fanous BS
J Clin Psychiatry; 1988 Aug; 49 Suppl():30-6. PubMed ID: 3045109
[TBL] [Abstract][Full Text] [Related]
28. The pharmacotherapy of depression.
Joffe RT
J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):4-9. PubMed ID: 1931936
[No Abstract] [Full Text] [Related]
29. [Current indications for antidepressants].
Tignol J
Encephale; 1994 Jun; 20 Spec No 2():261-3. PubMed ID: 8088242
[No Abstract] [Full Text] [Related]
30. Treatment of resistant depression with 5-HT uptake inhibitors.
Greden JF; Pande AC
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():442A-443A. PubMed ID: 1498908
[No Abstract] [Full Text] [Related]
31. [Age at initial use of antidepressive drugs].
Bouvard MP
Encephale; 1994 Jun; 20 Spec No 2():287-90. PubMed ID: 8088249
[No Abstract] [Full Text] [Related]
32. [Treatment of subsyndromes, or: consultation for chemotherapy of subsyndromes of depressive states].
Lecrubier Y
Encephale; 1994 Jun; 20 Spec No 2():265-6. PubMed ID: 8088243
[No Abstract] [Full Text] [Related]
33. [New discoveries on antidepressive treatment: serotonin is the key].
Evenden J
Lakartidningen; 1997 Sep; 94(38):3262-6. PubMed ID: 9379793
[No Abstract] [Full Text] [Related]
34. [Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs].
Goffinet S
Ann Med Psychol (Paris); 1993 Jan; 151(1):47-63. PubMed ID: 7905724
[TBL] [Abstract][Full Text] [Related]
35. The role of serotonin in depression and anxiety.
Baldwin D; Rudge S
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():41-5. PubMed ID: 7622823
[TBL] [Abstract][Full Text] [Related]
36. [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives].
Javelot H
Ann Pharm Fr; 2016 Mar; 74(2):93-118. PubMed ID: 26472602
[TBL] [Abstract][Full Text] [Related]
37. Fluvoxamine: clinical trials and clinical use.
Freeman CP
J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):19-25. PubMed ID: 1931932
[No Abstract] [Full Text] [Related]
38. [Antidepressive agents and somatic complaints].
Bouvet de La Maisonneuve O
Encephale; 1991 Dec; 17 Spec No 3():427-9. PubMed ID: 1807969
[TBL] [Abstract][Full Text] [Related]
39. Summary: defining remission in patients treated with antidepressants.
Thase ME
J Clin Psychiatry; 1999; 60 Suppl 22():35-6. PubMed ID: 10634354
[No Abstract] [Full Text] [Related]
40. Serotonin receptors: subtypes, functional responses and therapeutic relevance.
Saxena PR
Pharmacol Ther; 1995 May; 66(2):339-68. PubMed ID: 7667401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
